The Australian Medical Association Limited and state AMA entities comply with the Privacy Act 1988. Please refer to the AMA Privacy Policy to understand our commitment to you and information on how we store and protect your data.

×

Search

×

New treatment targets prostate cancer

Researchers at the Prostate and Breast Cancer Research Program at Monash University claim to have found a treatment using oestrogens to treat castrate-resistant cells in recurrent prostate cancer.

15 Mar 2010
Researchers at the Prostate and Breast Cancer ResearchProgram at Monash University claim to have found a treatment using oestrogensto treat castrate-resistant cells in recurrent prostate cancer, the most commoncancer in Australian men and the second most common cause in Australia ofcancer deaths in men.

They used a drug that is developed to activate selectivelyand specifically the beta oestrogen receptor in the prostate, which not only inhibits cancergrowth but also kills off cancer cells that are resistant to the conventionalandrogen deprivation therapy.

The researchers report discovering how this compound,working through the beta receptors, targets a small but important population ofcells in the tumour.

They made their discovery in animal models and thenreplicated laboratory results using human cells and tissues from patients withprostate cancer.


Published: 15 Mar 2010